"Novo Nordisk's Breakthrough Weight Loss Pill Poised to Outshine Competition"

Novo Nordisk CEO Lars Fruergaard Jørgensen believes the company's experimental weight loss pill, amycretin, could become a best-in-class treatment for obesity, potentially surpassing the success of its blockbuster drug Wegovy. Early-stage trial data showed patients on amycretin lost about 13.1% of their weight after 12 weeks, surpassing Wegovy's 6% weight loss. The pill targets gut hormone GLP-1 and pancreas hormone amylin, with a midstage trial expected to begin in the second half of 2022 and results anticipated in early 2026.